TARDBP and amyotrophic lateral sclerosis: Pathological aggregates of TDP-43 are implicated in Alzheimer’sdisease, frontotemporal dementia, and amyotrophic lateral sclerosis.While therapeutic efforts have traditionally focused on mitigatingend-stage TDP-43 aggregation, recent evidence highlights an upstreamand potentially targetable event: the loss of functional nuclear TDP-43multimers due to disrupted N-terminal domain (NTD) interactions.